共 50 条
- [45] Cellular senescence in the response of HR+ breast cancer to radiotherapy and CDK4/6 inhibitors Journal of Translational Medicine, 21
- [46] Are We Prepared for the CDK4/6 Revolution With HR+/HER2- Breast Cancers?: The Importance of Patient Adherence to Adjuvant Therapies BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2023, 17
- [49] Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer at a Single Cancer Center ONCOLOGIST, 2022, 27 (08): : 646 - 654